// App-Quantinova.ai

276 : Increased Levels of Endothelial Dysfunction Markers and Matrix Metalloproteinases in Patients with Severe Post-Thrombotic Syndrome

Researchers

Presenter

  • Luis Fernando Bittar

Principal Investigators

  • Fernanda Andrade Orsi

  • Kiara Cristina Senger Zapponi

  • Bruna Moraes Mazetto

  • Erich Vinicius De Paula Sr

  • Joyce Maria Annichino-Bizzacchi

Medical Centers

  • Faculty of Medical Sciences, Department of Clinical Pathology, University of Campinas, Campinas, SP, Brazil

  • Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil

  • Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil

Locations

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Vasodilation dysfunction

  • Venous thrombosis

Biomarkers

  • C-C Motif Chemokine Ligand 2

  • C reactive protein

  • C-C Motif Chemokine Ligand 5

  • C-Fos Induced Growth Factor

  • Platelet-Derived Growth Factor AB Heterodimer

  • D-dimer

  • Epidermal growth factor

  • E-selectin

  • Interleukin 1

  • Interleukin 10

  • Interleukin 13

  • Interleukin 6

  • Interleukin-8

  • Matrilysin

  • Matrix metallopeptidase 9

  • Matrix metalloproteinase 1

  • Matrix metalloproteinase 13

  • Matrix metalloproteinase 2

  • Soluble Vascular Cell Adhesion Molecule-1

  • TIMP Metallopeptidase Inhibitor 1

  • TIMP Metallopeptidase Inhibitor 2

  • Tumor necrosis factor

  • Vascular Endothelial Growth Factor C

Drug/Treatment

  • Thrombomodulin alfa

  • endothelin-1

  • sICAM-1

  • TIMP-2

  • FVIII

  • Interleukin-10

  • Becaplermin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved